Related Experiment Video
Updated: Nov 15, 2025
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview
1National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.
Abstract:
Biliary tract cancer (BTC) is a leading cause of cancer-related death, due to the limited benefits of current systematic therapies and the heterogeneity of the tumor itself. High heterogeneity means that the clinical and molecular features vary between different subtypes of BTC, while the underlying molecular mechanisms remain unclear. Targeted therapy, where inhibitors are developed to selectively combine with targeted molecules in order to block abnormal signaling pathways in BTC, has shown promise as an emerging form of treatment for various types of cancer. In this article, a comprehensive review is conducted to examine potential molecular targets for BTC targeted therapy and their mechanisms. Furthermore, preliminary data published from clinical trials is utilized to analyze the main drugs used to combat BTC. The collective information presented in this article has provided useful insights into the current understanding of BTC.
Insights
Biliary tract cancer (BTC) is a deadly cancer with limited treatment options due to its complexity. This review explores targeted therapy options and drugs for BTC, offering insights into current understanding and future directions.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Biliary tract cancer (BTC) presents a significant global health challenge, contributing substantially to cancer mortality.
- Current systemic therapies for BTC offer limited efficacy, underscoring the need for novel treatment strategies.
- The high heterogeneity of BTC, characterized by diverse clinical and molecular features across subtypes, complicates therapeutic development.
Purpose of the Study:
- To conduct a comprehensive review of potential molecular targets for targeted therapy in biliary tract cancer (BTC).
- To elucidate the mechanisms of action for these potential molecular targets.
- To analyze current drugs used in BTC treatment based on preliminary clinical trial data.
Main Methods:
- Literature review of scientific articles and clinical trial data related to BTC targeted therapy.
- Systematic examination of molecular targets and their associated signaling pathways in BTC.
- Analysis of efficacy and safety data from ongoing and completed clinical trials for BTC drugs.
Main Results:
- Identification of several promising molecular targets crucial for BTC progression and survival.
- Detailed description of the mechanisms through which targeted therapies can inhibit BTC growth.
- Overview of key drugs currently under investigation or in use for BTC, with preliminary efficacy data.
Conclusions:
- Targeted therapy represents a promising avenue for improving outcomes in biliary tract cancer (BTC).
- Understanding BTC heterogeneity is critical for selecting appropriate molecular targets and tailoring treatments.
- Further clinical investigation and drug development are essential to fully realize the potential of targeted therapies for BTC.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
07:36Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...